A Prospective, Non-Interventional Study in Germany to Evaluate the Long-Term Effectiveness and Tolerability of Subcutaneously Administered RoActemra (Tocilizumab; TCZ) in Patients With Rheumatoid Arthritis in Daily Clinical Practice (as Recommended in Label)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2018
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ARATA
- Sponsors Roche
- 24 Jul 2018 Planned End Date changed from 31 May 2019 to 30 May 2020.
- 24 Jul 2018 Planned primary completion date changed from 31 May 2019 to 30 May 2020.
- 24 Jul 2018 Status changed from recruiting to active, no longer recruiting.